Drugs / BVS857
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01435330 | Mar 2011 → Mar 2012 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT02024932 | Feb 2014 → Apr 2016 | bulbospinal muscular atrophy | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT02074995 | Feb 2014 → Jan 2015 | hypoproteinemia, hypercatabolic | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BVS857 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01435330 ↗ |
| Route | Intravenous | “administered either i.v. or s.c..” NCT02024932 ↗ |
| Route | Subcutaneous | “administered either i.v. or s.c..” NCT02024932 ↗ |